FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Watler Peter K.

2. Date of Event Requiring Statement (MM/DD/YYYY)
11/5/2014 

3. Issuer Name and Ticker or Trading Symbol

Coherus BioSciences, Inc. [CHRS]

(Last)        (First)        (Middle)

COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
Chief Technical Officer /

(Street)

REDWOOD CITY, CA 94065       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

11/6/2014 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)     (1) 12/13/2022   Common Stock   142494   $2.0838   D    
Stock Option (Right to Buy)     (2) 11/21/2023   Common Stock   44990   $1.417   D    
Stock Option (Right to Buy)     (3) 6/29/2024   Common Stock   29993   $2.5005   D    
Stock Option (Right to Buy)     (4) 2/27/2023   Common Stock   56988   $2.0838   I   By Wife  
Stock Option (Right to Buy)     (2) 11/21/2023   Common Stock   59988   $1.417   I   By Wife  
Stock Option (Right to Buy)     (5) 6/29/2024   Common Stock   29994   $2.5005   I   By Wife  

Explanation of Responses:
( 1)  A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from March 19, 2012 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
( 2)  A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from July 30, 2013, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
( 3)  A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from June 30, 2014, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
( 4)  A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: Twenty Five Percent (25%) of the shares subject to the option vest one year measured from June 4, 2012 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
( 5)  A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from May 29, 2014, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Watler Peter K.
COHERUS BIOSCIENCES, INC.
333 TWIN DOLPHIN DRIVE, SUITE 600
REDWOOD CITY, CA 94065


Chief Technical Officer

Signatures
/s/ Jean Frederic Viret, as Attorney-in-Fact for Peter K. Watler, Ph.D. 5/4/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Coherus BioSciences Charts.
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Coherus BioSciences Charts.